Ventyx Biosciences Inc
VTYX2.690USD
+0.060+2.28%
交易中 （美東）報價延遲15分鐘
191.42M總市值
虧損本益比TTM
關於 Ventyx Biosciences Inc 公司
Ventyx Biosciences, Inc. 是一家臨牀階段生物製藥公司。該公司專注於開發一系列小分子候選產品，以解決一系列尚未得到滿足的炎症疾病需求。該公司的產品線包括 VTX002（S1P1R 調節劑）、VTX958（TYK2 抑制劑）以及 VTX2735 和 VTX3232（NLRP3 抑制劑組合）。VTX002 是一種鞘氨醇 1 磷酸受體 (S1P1R) 調節劑，目前處於 II 期開發階段，用於治療中度至重度活動性潰瘍性結腸炎 (UC) 患者。VTX958 是一種口服、選擇性臨牀階段酪氨酸激酶 2 型 (TYK2) 抑制劑，TYK2 是 Janus 激酶 (JAK) 家族中的一種細胞內信號激酶，可調節免疫介導疾病中的慢性炎症。該公司的第三款候選產品 VTX2735 是一種針對外周的 NOD 樣受體蛋白 3 (NLRP3) 炎症小體抑制劑。除了 VTX2735，該公司還在開發 VTX3232，這是該公司處於第 1 階段開發中的領先 CNS 滲透性 NLRP3 抑制劑。
公司簡介
公司代碼VTYX
公司名稱Ventyx Biosciences Inc
上市日期Oct 21, 2021
CEOMr. Raju Mohan, Ph.D.
員工數量79
證券類型Ordinary Share
年結日Oct 21
公司地址12790 El Camino Real, Suite 200
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92130
電話18589452393
網址https://ventyxbio.com/
公司代碼VTYX
上市日期Oct 21, 2021
CEOMr. Raju Mohan, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Roy M. Gonzales
Mr. Roy M. Gonzales
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. William R. White, J.D.
Mr. William R. White, J.D.
Independent Director
Independent Director
--
--
Ms. Onaiza Cadoret - Manier
Ms. Onaiza Cadoret - Manier
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Moore
Mr. Matthew (Matt) Moore
Chief Operating Officer
Chief Operating Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月1日 週日
更新時間: 6月1日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Point72 Asset Management, L.P.
5.95%
Affinity Asset Advisors LLC
5.70%
BlackRock Institutional Trust Company, N.A.
5.69%
New Science Ventures, LLC
5.67%
The Vanguard Group, Inc.
4.94%
Other
72.05%
持股股東
持股股東
佔比
Point72 Asset Management, L.P.
5.95%
Affinity Asset Advisors LLC
5.70%
BlackRock Institutional Trust Company, N.A.
5.69%
New Science Ventures, LLC
5.67%
The Vanguard Group, Inc.
4.94%
Other
72.05%
股東類型
持股股東
佔比
Hedge Fund
29.49%
Investment Advisor
18.75%
Investment Advisor/Hedge Fund
16.10%
Venture Capital
5.74%
Individual Investor
4.12%
Research Firm
3.60%
Family Office
0.27%
Bank and Trust
0.17%
Pension Fund
0.07%
Other
21.71%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
365
55.53M
78.03%
-48.49M
2025Q1
385
51.70M
72.65%
-54.51M
2024Q4
397
65.14M
91.63%
-35.16M
2024Q3
387
62.43M
88.32%
-37.01M
2024Q2
376
67.39M
95.54%
-30.30M
2024Q1
369
70.49M
100.19%
-8.56M
2023Q4
345
54.61M
92.50%
-19.94M
2023Q3
315
66.31M
112.60%
-5.18M
2023Q2
302
65.66M
112.13%
-3.35M
2023Q1
267
64.47M
110.86%
+4.32M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Point72 Asset Management, L.P.
4.23M
5.95%
+2.45M
+137.64%
Mar 31, 2025
Affinity Asset Advisors LLC
4.06M
5.7%
+4.06M
--
May 22, 2025
BlackRock Institutional Trust Company, N.A.
4.05M
5.69%
-66.25K
-1.61%
Mar 31, 2025
New Science Ventures, LLC
4.03M
5.67%
-3.07M
-43.23%
Mar 28, 2025
The Vanguard Group, Inc.
3.51M
4.94%
+5.11K
+0.15%
Mar 31, 2025
Tang Capital Management, LLC
3.10M
4.36%
--
--
Mar 31, 2025
Sio Capital Management, LLC
2.58M
3.63%
-1.46M
-36.18%
Mar 31, 2025
Mohan (Raju)
2.30M
3.24%
--
--
Apr 10, 2025
Vestal Point Capital, LP
2.00M
2.81%
--
--
Mar 31, 2025
Redmile Group, LLC
1.57M
2.21%
+1.45M
+1164.15%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.57%
iShares Micro-Cap ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Fidelity MSCI Health Care Index ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Biotechnology ETF
0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.57%
iShares Micro-Cap ETF
佔比0.03%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
Fidelity MSCI Health Care Index ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
iShares Biotechnology ETF
佔比0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
